• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Future Cardiol . SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges

tetano

Editor, Senior Moderator
Future Cardiol


. 2021 Mar 19.
doi: 10.2217/fca-2020-0188. Online ahead of print.
SARS-CoV-2 as an inflammatory cardiovascular disease: current knowledge and future challenges


Kevin S Shah[SUP] 1 [/SUP], Mary Elizabeth Hale Hammond[SUP] 2 [/SUP], Stavros G Drakos[SUP] 1 3 [/SUP], Jeffrey L Anderson[SUP] 2 [/SUP], James C Fang[SUP] 1 [/SUP], Kirk U Knowlton[SUP] 4 [/SUP], Robin M Shaw[SUP] 3 [/SUP]



Affiliations

Abstract

SARS-CoV-2 is responsible for the 2020 global coronavirus disease 2019 (COVID-19) pandemic. In patients with COVID-19, multiple cardiovascular (CV) manifestations have been reported. SARS coronavirus 2 infection can lead to inflammatory CV disease first via takeover of the angiotensin-converting enzyme-2 enzyme as a cell receptor as well as the macrophage activation syndrome in severe illness. We review the CV manifestations of COVID-19 and therapeutics under investigation. We discuss the potential long-term CV sequelae after recovery from COVID-19 and the gaps in knowledge including the pathophysiological links between acute cardiac injury, myocardial inflammation and chronic cardiomyopathy. Future investigational efforts could result in significant diagnostic and therapeutic advances potentially impacting the broader field of chronic heart failure and cardiac recovery.

Keywords: COVID-19; cardiomyopathy; cardiovascular system; myocardial injury; myocarditis.


Plain Language Summary

Lay abstract COVID-19 has led to a global pandemic, and many patients infected with this novel virus develop cardiovascular (CV) complications including heart attacks, strokes, heart failure and sudden cardiac death. We will review the pathophysiology behind how a viral infection can place a patient at risk and cause multiple CV diseases. Additionally, we will review our current knowledge regarding treatment for the novel corona virus and long-term risk for patients who recover from COVID-19. At last, we will discuss the future perspective regarding what we can learn about how a virus can cause CV disease and how we can better equip ourselves for future pandemics.
 
Back
Top Bottom